This is a preview of subscription content, log in via an institution to check access.
References
Gokbuget N, Hoelzer D (2009) Treatment of adult acute lymphoblastic leukemia. Semin Hematol 46(1):64–75. doi:10.1053/j.seminhematol.2008.09.003
Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120(10):2032–2041. doi:10.1182/blood-2011-12-399287
Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Bruggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134–4140. doi:10.1200/JCO.2014.56.3247
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Stieglmaier J, Wessels H, Haddad V, Zugmaier G, Nagorsen D, Bargou RC (2015) Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood 126(23):680–680
Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM (2011) Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol 49(6):2151–2153. doi:10.1128/JCM.00256-11
Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P (2008) Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 46(6):567–573. doi:10.1080/13693780801975576
Benjamin JE, Stein AS (2016) The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol 7(3):142–156. doi:10.1177/2040620716640422
Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Kohne-Volland R, Bruggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmuller G, Hoelzer D, Zugmaier G, Bargou RC (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29(18):2493–2498. doi:10.1200/JCO.2010.32.7270
Tasian SK, Gardner RA (2015) CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol 6(5):228–241. doi:10.1177/2040620715588916
Kranick S, Phan G, Kochenderfer J, Rosenberg S, Nath A (2014) Aphasia as a complication of CD19-targeted chimeric antigen receptor immunotherapy. Neurology 82(no. 10 Supplement):S52.006
Acknowledgments
This work was supported by a grant from the medical faculty of the University of Muenster.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Vogt, N., Heß, K., Bialek, R. et al. Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia. Ann Hematol 96, 151–153 (2017). https://doi.org/10.1007/s00277-016-2837-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2837-1